Irritable bowel syndrome: Newer pharmacological agents acting on the gut

Research output: Contribution to journalArticlepeer-review

1 Scopus citations


The objectives of this brief review are to provide an update on the clinical pharmacology and clinical trials of new potential therapies for irritable bowel syndrome (IBS). These medications include: 5-HT3 antagonists, 5-HT4 agonists, α2-adrenergic agonists, κ opioid agonists, neurokinin antagonists, neostigmine, probiotics and antibiotics. While these approaches offer promise and a substantial rationale based on modulating the brain gut axis, the potential for central effects and the clinical efficacy of some of these agents are still being explored, and proof of concept studies needs to be supported by robust evidence of positive risk–benefit.

Original languageEnglish (US)
Pages (from-to)143-148
Number of pages6
JournalInternational Congress Series
Issue numberC
StatePublished - Sep 1 2002


  • Clonidine
  • IBS
  • Neurokinin
  • Probiotics
  • Serotonin

ASJC Scopus subject areas

  • General Medicine


Dive into the research topics of 'Irritable bowel syndrome: Newer pharmacological agents acting on the gut'. Together they form a unique fingerprint.

Cite this